Investor Overview

Investor Overview

Corporate Profile

Y-mAbs Therapeutics Inc. (Y-mAbs) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer based on a range of technologies licensed from Memorial Sloan Kettering Cancer Center. Its mission is to become the world leader in developing better and safer antibody-based pediatric oncology products addressing clear unmet medical needs. Y-mAbs also seeks to advance and expand its product pipeline into certain adult cancer indications and to leverage its extensive drug development capabilities and platform technology towards the creation of new types of bispecific antibodies.

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Nov 25, 2020

FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma

Nov 19, 2020

Y-mAbs Announces Update on Omburtamab in DIPG

Nov 05, 2020

Y-mAbs Announces Third Quarter 2020 Financial Results and Recent Corporate Developments